Otro objetivo del estudio era la prdida de peso, y el frmaco tambin lo consigui: los participantes que tomaron semaglutida perdieron en torno al 13 % de su peso corporal, frente al 2,6 % de los que tomaron placebo, en el transcurso del ensayo, que dur un ao
Among people with celiac disease, 95 percent have the HLA-DQ2 gene, and most of the rest of that remaining 5 percent have the HLA-DQ8 gene
Fezolinetant was initially for treatment of hot flashes in menopause
Weight loss is a recognised side effect of topiramate but does not constitute a licensed indication
Mounjaro launched in Canada in November 2024 for type 2 diabetes
Public regulatory communications emphasize the importance of reviewing platform compliance standing, pharmacy licensure status, and provider credentials when evaluating telehealth services